socalTECH

SEPTEMBER 11, 2019

San Diego-based biotech investor Avalon Ventures has scored an exit, saying late Tuesday evening that it has entered into a definitive agreement with GlaxoSmithKline (GSK), to sell Sitari Pharmaceuticals to GSK. Sitari was developing treatments for celiac disease, and was being incubated at COI Pharmaceuticals.

Avalon 100

Avalon San Diego Incubator Develop 100

Xconomy

SEPTEMBER 11, 2019

GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.

Avalon 56

Avalon Invest Southern California Develop 56

socalTECH

JULY 14, 2017

San Diego-based StackIQ , a developer of "bare metal" provisioning software, has been acquired by Teradata , Teradata said on Thursday. Financial terms of the acquisition were not announced. StackIQ was venture backed by Anthem Venture Partners, Grayhawk Capital, Avalon Ventures, and crowdfunding site OurCrowd. READ MORE>>.

Avalon 113

Avalon Anthem San Diego Acquisition 113

socalTECH

JUNE 11, 2021

The company begins trading this morning on the Nasdaq Global market under the ticker symbol JANX. According to the company, the gross proceeds from the effort are expected to be $193.8M. Janux Therapeutics is developing T cell engager immunotherapies.

Pricing 113

Pricing Avalon Capital Marketing 113

socalTECH

NOVEMBER 13, 2019

San Diego-based COI Pharmaceuticals , the life sciences incubator and support entity created by Avalon Ventures to support its portfolio companies, says that one of its companies, Calporta Therapeutics , has been acquired by Merck. The deal is worth up to $576M, including upfront payments and contingent milestone payments.

Avalon 124

Avalon San Diego Incubator Technology 124

socalTECH

AUGUST 13, 2014

The company was trading around $17.52 The company raised $100M in the IPO. The company priced at the high end of its initial estimated IPO range, which was $14.00 The company is developing treatments for disorders of the inner ear. otonomy merger acquisition biotech lifescience otic nasdaq exit' READ MORE>>.

Avalon 138

Avalon San Diego Pricing Acquisition 138

socalTECH

JANUARY 17, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has set its estimated IPO pricing range, saying on Tuesday that it expects to price its IPO at between $14.00 The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB. and $16.00 as early as Thursday.

Pricing 100

Pricing Avalon Southern California Venice 100